PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus

A Principal, Open-Label, Single Center Study to Validate the Detection of Cerebral Cortical Amyloid With Flutemetamol (18F) Injection in Subjects Previously Biopsied

This study will determine the level of association between the quantitative estimates of brain uptake of [18F]flutemetamol and the quantitative immunohistochemical estimates of amyloid levels in biopsy samples previously obtained during shunt placement in patients who have normal pressure hydrocephalus (NPH).

Inclusion Criteria:

• The subject is 50 years old or older.
• The subject has had a frontal lobe cortical biopsy adequate for the detection and quantitation of amyloid.
• Informed consent has been signed and dated by the subject/and/or subjects' legally acceptable representative, if applicable, in accordance with local regulations.

Exclusion Criteria:

• The subject has a contraindication for MRI or PET.
• The subject has a known or suspected hypersensitivity/allergy to [18F]flutemetamol.
• The subject has participated in any clinical study using an investigational agent within 30 days of dosing.